|
Gene: H3F3A |
Gene summary for H3F3A |
Gene summary. |
Gene information | Species | Human | Gene symbol | H3F3A | Gene ID | 3020 |
Gene name | H3.3 histone A | |
Gene Alias | H3-3B | |
Cytomap | 1q42.12 | |
Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | B2R4P9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3020 | H3F3A | P52T-E | Human | Esophagus | ESCC | 2.71e-154 | 4.34e+00 | 0.1555 |
3020 | H3F3A | P54T-E | Human | Esophagus | ESCC | 8.41e-127 | 4.55e+00 | 0.0975 |
3020 | H3F3A | P56T-E | Human | Esophagus | ESCC | 1.21e-30 | 5.61e+00 | 0.1613 |
3020 | H3F3A | P57T-E | Human | Esophagus | ESCC | 9.84e-146 | 3.78e+00 | 0.0926 |
3020 | H3F3A | P61T-E | Human | Esophagus | ESCC | 5.54e-119 | 4.12e+00 | 0.099 |
3020 | H3F3A | P62T-E | Human | Esophagus | ESCC | 1.67e-164 | 4.75e+00 | 0.1302 |
3020 | H3F3A | P65T-E | Human | Esophagus | ESCC | 6.08e-152 | 4.14e+00 | 0.0978 |
3020 | H3F3A | P74T-E | Human | Esophagus | ESCC | 1.87e-102 | 5.31e+00 | 0.1479 |
3020 | H3F3A | P75T-E | Human | Esophagus | ESCC | 5.47e-158 | 4.87e+00 | 0.1125 |
3020 | H3F3A | P76T-E | Human | Esophagus | ESCC | 6.50e-159 | 4.83e+00 | 0.1207 |
3020 | H3F3A | P79T-E | Human | Esophagus | ESCC | 3.15e-159 | 4.78e+00 | 0.1154 |
3020 | H3F3A | P80T-E | Human | Esophagus | ESCC | 1.28e-96 | 5.27e+00 | 0.155 |
3020 | H3F3A | P82T-E | Human | Esophagus | ESCC | 3.03e-60 | 4.88e+00 | 0.1072 |
3020 | H3F3A | P83T-E | Human | Esophagus | ESCC | 2.96e-103 | 4.81e+00 | 0.1738 |
3020 | H3F3A | P84T-E | Human | Esophagus | ESCC | 3.55e-52 | 4.28e+00 | 0.0933 |
3020 | H3F3A | P89T-E | Human | Esophagus | ESCC | 1.77e-50 | 5.14e+00 | 0.1752 |
3020 | H3F3A | P91T-E | Human | Esophagus | ESCC | 4.03e-32 | 5.72e+00 | 0.1828 |
3020 | H3F3A | P94T-E | Human | Esophagus | ESCC | 2.56e-20 | 4.12e+00 | 0.0879 |
3020 | H3F3A | P104T-E | Human | Esophagus | ESCC | 3.66e-39 | 3.47e+00 | 0.0931 |
3020 | H3F3A | P107T-E | Human | Esophagus | ESCC | 2.59e-138 | 4.81e+00 | 0.171 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa05131110 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa0513125 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
hsa0513135 | Cervix | HSIL_HPV | Shigellosis | 27/459 | 247/8465 | 3.78e-04 | 3.49e-03 | 2.82e-03 | 27 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
H3F3A | SNV | Missense_Mutation | c.307G>T | p.Gly103Cys | p.G103C | P84243 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.949) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
H3F3A | SNV | Missense_Mutation | novel | c.25C>G | p.Arg9Gly | p.R9G | P84243 | protein_coding | deleterious_low_confidence(0.05) | benign(0.001) | TCGA-E2-A573-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
H3F3A | SNV | Missense_Mutation | c.7N>G | p.Arg3Gly | p.R3G | P84243 | protein_coding | tolerated_low_confidence(0.06) | benign(0) | TCGA-E9-A1R3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | methotrexate | SD | |
H3F3A | SNV | Missense_Mutation | c.7C>T | p.Arg3Cys | p.R3C | P84243 | protein_coding | deleterious_low_confidence(0.01) | benign(0.001) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
H3F3A | SNV | Missense_Mutation | novel | c.8G>C | p.Arg3Pro | p.R3P | P84243 | protein_coding | deleterious_low_confidence(0.03) | benign(0) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
H3F3A | SNV | Missense_Mutation | c.14N>T | p.Lys5Met | p.K5M | P84243 | protein_coding | deleterious_low_confidence(0) | benign(0.271) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
H3F3A | SNV | Missense_Mutation | novel | c.274G>T | p.Ala92Ser | p.A92S | P84243 | protein_coding | deleterious_low_confidence(0) | benign(0.284) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
H3F3A | SNV | Missense_Mutation | c.385N>T | p.Arg129Cys | p.R129C | P84243 | protein_coding | tolerated_low_confidence(0.09) | benign(0.001) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
H3F3A | SNV | Missense_Mutation | c.389G>A | p.Arg130His | p.R130H | P84243 | protein_coding | tolerated_low_confidence(0.08) | benign(0.001) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
H3F3A | SNV | Missense_Mutation | c.245N>T | p.Asp82Val | p.D82V | P84243 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.858) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |